The FDA has granted orphan drug designation to PEP-010 for pancreatic cancer, advancing its development as a potential novel ...

The management of breast cancer involves various therapeutic approaches. However, many current anticancer treatments indiscriminately damage both cancerous and healthy cells. In cancer treatment, ...

PEP-Therapy is a Paris-based clinical-stage biotechnology company developing first-in-class peptides as targeted therapies in oncology. PEP-010, lead drug candidate, is a pro-apoptotic agent currently ...

The extract worked wonders by up-regulating pro-apoptotic proteins (Caspase 3, Caspase 9, and P53) while down-regulating BcL2, a key protein that helps cancer cells survive. “Molecular docking ...

and upregulating apoptotic genes such as Caspase 3 and 9, as well as influencing or activating the p53 gene. The F12 product ...

Q4 2024 Results Conference Call March 20, 2025 8:00 AM ET. Company Participants. Andrew Funderburk - Senior Vice President, Investor Re ...

To test whether rapamycin could induce apoptosis of tumour cells, we performed IHC for cleaved caspase 3. Tumours harvested from mice 3–4, 7–9 and >21 days post-treatment were assessed, and we found ...

Researchers have shed new light on how tissues in the body are repaired following the damage and premature death of tissue ...

Lomond Therapeutics Holdings, Inc. ("Lomond Therapeutics"), a clinical-stage biotechnology company dedicated to discovering ...